Glaukos Co. (NYSE:GKOS - Get Free Report) traded down 9.8% during trading on Monday . The company traded as low as $94.60 and last traded at $94.00. 661,123 shares were traded during mid-day trading, a decline of 16% from the average session volume of 791,675 shares. The stock had previously closed at $104.19.
Wall Street Analyst Weigh In
A number of research firms have recently commented on GKOS. Wells Fargo & Company lifted their target price on Glaukos from $153.00 to $160.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. Needham & Company LLC lifted their price target on Glaukos from $149.00 to $176.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Stephens upgraded Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. BTIG Research raised their target price on shares of Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a research report on Tuesday, November 26th. Finally, Stifel Nicolaus upped their price target on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $163.25.
Get Our Latest Report on Glaukos
Glaukos Price Performance
The stock has a fifty day moving average of $143.84 and a two-hundred day moving average of $138.41. The stock has a market cap of $5.83 billion, a price-to-earnings ratio of -35.93 and a beta of 0.99. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.
Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, equities research analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.
Insider Buying and Selling at Glaukos
In related news, Director Gilbert H. Kliman sold 10,000 shares of Glaukos stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at $4,859,454.08. The trade was a 23.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total value of $502,630.24. Following the sale, the insider now owns 72,437 shares in the company, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 16,744 shares of company stock valued at $2,504,131. Corporate insiders own 6.40% of the company's stock.
Institutional Trading of Glaukos
Several institutional investors and hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc purchased a new position in Glaukos in the 4th quarter valued at about $43,000. Asset Planning Inc purchased a new position in shares of Glaukos during the fourth quarter valued at approximately $90,000. CoreCap Advisors LLC boosted its position in Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock worth $112,000 after acquiring an additional 200 shares during the last quarter. Harvest Fund Management Co. Ltd grew its stake in Glaukos by 2,263.2% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after acquiring an additional 860 shares during the period. Finally, Picton Mahoney Asset Management acquired a new position in Glaukos in the 4th quarter valued at $125,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.
About Glaukos
(
Get Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
See Also
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
